RedHill Biopharma Advances Opaganib For Ebola Treatment With BARDA Funding, Aiming To Tackle Global Health Preparedness
RedHill Biopharma Advances Opaganib For Ebola Treatment With BARDA Funding, Aiming To Tackle Global Health Preparedness
redhill biopharma正在利用BARDA資金推進Opaganib用於埃博拉治療，旨在解決全球衛生應對準備工作。
- The U.S. government's Biomedical Advanced Research and Development Authority (BARDA) selected opaganib for joint development & funding as a medical countermeasure (MCM) to treat Ebola virus disease (EBOV)
- The funding advances opaganib's positive development progress to date on the expected FDA Animal Rule pathway toward potential approval as an MCM for EBOV
- Recent U.S. Army-funded studies showed that opaganib delivered a statistically significant increase in survival in an in vivo EBOV model. The BARDA research and development contract provides initial funding for the collaboration, in pursuit of advancing opaganib to mitigate infection and contain EBOV outbreaks
- This year marks the 10th anniversary of the West Africa Ebola epidemic in which 11,000 people died, and there is still an urgent need for effective and useable therapies, with EBOV proving fatal in around half of all cases according to the World Health Organization (WHO)1
- Opaganib, a novel potentially broad-acting drug, has shown mutation-resistant antiviral and anti-inflammatory activity, likely to directly impact vascular health - one of the main targets for EBOV dysfunction. It is believed to be the first host-directed molecule to show activity in EBOV in vivo and represents an alternative host-directed therapeutic strategy for biodefense and global health preparedness. Additional U.S. government collaborations with opaganib are ongoing
- Significant geopolitical and logistical challenges exist in managing outbreaks of disease and there is an urgent need for safe and effective, oral, small molecule therapeutics that can be stored and easily distributed and administered in an outbreak
- 美國政府生物醫學高級研究與發展局（BARDA）選擇奧帕加尼布進行聯合開發和資助，作爲治療埃博拉病毒病（EBOV）的醫療對策（MCM）
- 這筆資金推動了奧帕加尼布迄今爲止在預期的美國食品藥品管理局動物規則途徑上取得的積極進展，該路徑有可能被批准爲EBOV的MCM
- 最近由美國陸軍資助的研究表明，在體內 EBOV 模型中，奧帕加尼布的存活率在統計學上顯著提高。BARDA的研發合同爲合作提供了初始資金，旨在推進opaganib以減輕感染和遏制埃博病毒疫情
- 今年是西非埃博拉疫情十週年，該疫情造成11,000人死亡，但仍然迫切需要有效和可用的療法，根據世界衛生組織（WHO）的數據，在所有病例中，約有一半的埃博拉病毒已被證明是致命的 1
- 奧帕加尼布是一種新型的潛在廣效藥物，已顯示出耐突變的抗病毒和抗炎活性，可能直接影響血管健康，血管健康是EBOV功能障礙的主要靶標之一。據信，它是第一個在體內顯示出EBOV活性的宿主導分子，是生物防禦和全球健康防範的替代宿主導治療策略。美國政府與奧帕加尼布的其他合作正在進行中
- 在管理疾病疫情方面存在重大地緣政治和後勤挑戰，迫切需要安全有效的口服小分子療法，這種療法可以在疫情中儲存、易於分發和使用
資訊熱榜
更新時間